about
T cell allorecognition via molecular mimicryAffinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A virusesPreemptive priming readily overcomes structure-based mechanisms of virus escapeOseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza VirusesConsiderations for the rapid deployment of vaccines against H7N9 influenza.Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza.Prior population immunity reduces the expected impact of CTL-inducing vaccines for pandemic influenza control.Establishment of functional influenza virus-specific CD8(+) T cell memory pools after intramuscular immunization.Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenzaRole of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development.The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.Impaired dendritic cell maturation in response to pandemic H1N109 influenza virus.Identification of dominant epitopes of synthetic immunocontraceptive vaccines that induce antibodies in dogs.Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes.Isolation of antibodies specific to a single conformation-dependant antigenic determinant on the EG95 hydatid vaccine.Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectinsA phase I clinical trial of dendritic cell immunotherapy in HCV-infected individualsIdentification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2)Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals.Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responsesThe central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer.A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design.Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy.Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2CysProspects for dendritic cell vaccination in persistent infection with hepatitis C virusMesenchymal stem cell-based cartilage tissue engineering: cells, scaffold and biology.A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infectionAnalysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.Memory cytolytic T-lymphocytes: induction, regulation and implications for vaccine design.Lipid-based self-adjuvanting vaccines.Enumeration of antigenic sites of influenza virus hemagglutinin.Hierarchical self-tolerance to T cell determinants within the ubiquitous nuclear self-antigen La (SS-B) permits induction of systemic autoimmunity in normal mice.Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of hostClass II-restricted T-cell clones to a synthetic peptide of influenza virus hemagglutinin differ in their fine specificities and in the ability to respond to virus.Direct role of viral hemagglutinin in B-cell mitogenesis by influenza viruses.Recent advances with TLR2-targeting lipopeptide-based vaccines.
P50
Q27658914-67604B92-A05B-4502-AC6A-FF7BBA7C5DF8Q27675301-3A0C87E2-2A4D-4CDB-9A53-D18CF4752534Q27676834-4C826B43-6500-489B-92FC-2CB7C95CD41BQ28548477-A83A3E1F-96E3-47B0-8139-69E24BCB5084Q30364635-80645C48-9254-4D20-AF54-C183A4383826Q30369956-798192EC-5870-4338-BBC7-4BEF32D38ACDQ30373077-E588AA2D-3316-4C8E-88E1-69537CA8BE1BQ30377948-570DA839-6F0F-485B-BB1C-C839FB8751D3Q30379213-A3E848D0-1BE6-4672-B0BE-820D22ABFB5EQ30389274-0B6F3306-AAFE-4BA1-B0A4-47FE4F29F074Q30423530-2B3A7943-1588-4189-B1EC-532156377527Q30424477-AFFDEB0F-DE9E-434B-9D46-E8A3CB231CF9Q33216211-D3DC716B-8320-4A40-8EEB-91BC1655FBC0Q33273910-B2B0057E-1AFD-43F7-AFE4-7027293CF82AQ33394452-56C7D9E4-B354-47FA-B0D0-FFCF696A4AA3Q33629099-A31E6684-B64D-4851-B2F6-50B48509BB8AQ34091925-8438BFF7-1F9C-48E9-A627-13F63EDC61C7Q34168560-0C711CB9-72E9-48FF-96A7-F95C2689C79FQ34384186-CF514546-68F1-4259-B64B-C7A3F76774AFQ34455275-BD0B134A-4F87-4D0C-A9BC-661939D44481Q34604195-EAC4CF0B-1FF4-4448-A2C0-672D54C770BBQ34787042-D57CAA66-9354-48E5-A0B1-C7EBB58BBFE4Q34998462-28686EDD-FCD8-4C39-A977-6E8E80540D7CQ35152953-9E923148-1A08-4684-82A1-068B6B84FCE5Q35635696-891F3EB3-0B62-4E00-A5E3-4C5FB3DCDBB3Q35687079-D3478BC1-730E-4EB1-9679-213869623F5DQ35784239-FBC063C2-17D2-48FD-A991-9C067793667AQ35809259-54EBDA43-4365-462B-998E-F2E973326B8EQ35920476-DF976DC5-F270-4078-AFEF-47D993EBF647Q36045018-7B3072DD-65C4-4E82-847F-540CD61FD944Q36227268-B6A4A562-C2D8-4767-9323-6780AD94C10DQ36284560-C0256168-1DE3-47EF-874C-FE9AD0318EE9Q36320814-1101AEB0-B27D-4A8E-AAE0-2B4DB00539B1Q36332743-937A81DB-CF68-4DBD-86D1-6123C32726B4Q36367698-2BA97D0F-3A60-4AA0-AE3B-F2161F34C63EQ36545925-14D02CCF-F166-4DBC-9D2F-B3DC54A3EFA6Q36774253-5C43E179-C6DB-4FB8-80B9-F13E6FC53625Q36829395-FC3C2682-F16C-4135-9045-72185B976C47Q36907127-B43BC8E8-BE1C-42F7-BB19-766C2DFB4DABQ36909432-0CDB71A7-DCDE-4A02-9A71-B35F86572F18
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David Jackson
@ast
David Jackson
@en
David Jackson
@es
David Jackson
@nl
David Jackson
@sl
Давид Джексон
@ru
type
label
David Jackson
@ast
David Jackson
@en
David Jackson
@es
David Jackson
@nl
David Jackson
@sl
Давид Джексон
@ru
prefLabel
David Jackson
@ast
David Jackson
@en
David Jackson
@es
David Jackson
@nl
David Jackson
@sl
Давид Джексон
@ru
P106
P1153
13003942900
P21
P2798
P31
P496
0000-0001-7255-270X